Sfoglia per Autore "Drakoulis, C."
Items 1-8 di 8
-
HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
Goulis, L.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M. P.; Drakoulis, C.; Mimidis, K.; Germanidis, G.; Nikolopoulou, V.; Chounta, A.; Bakalos, G.; Papatheodoridis, G. V. (2011) -
HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C.; Drakoulis, C.; Chounta, A.; Tsoplou, F.; Zintzaras, E.; Bakalos, G.; Papatheodoridis, G. (2012) -
HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Drakoulis, C.; Bakalos, G.; Papatheodoridis, G. (2011) -
HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY
Papatheodoridis, G.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K. M.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G.; HepNet Greece Study, Grp (2013) -
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ... -
IL28B polymorphisms as predictors of response to peginterferon-alfa-2a in HBeAg-negative chronic hepatitis B
Papatheodoridis, G. V.; Gatselis, N.; Goulis, I.; Karatapanis, S.; Deutsch, M.; Mimidis, K.; Drakoulis, C.; Akriviadis, E. A.; Dalekos, G. N. (2013) -
On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
Goulis, I.; Karatapanis, S.; Akriviadis, E. A.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C. K.; Drakoulis, C.; Chounta, A.; Vafiadis, I.; Hatzis, G.; Gagalis, A.; Vlachogiannakos, J.; Zintzaras, E.; Koulouris, S.; Bakalos, G.; Papatheodoridis, G. V. (2013) -
On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients
Goulis, I.; Karatapanis, S.; Akriviadis, E.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Drakoulis, C.; Triantos, C.; Zintzaras, E.; Bakalos, G.; Papatheodoridis, G. (2015)Background & AimsWe assessed predictors of response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a in routine clinical practice. MethodsNinety-five HBeAg-negative patients received ...